<DOC>
	<DOCNO>NCT01667224</DOCNO>
	<brief_summary>Obesity major health issue worldwide ; constant raise obesity relate death year . In vitro animal study elucidate Actiponin novel anti-obesity agent . However , efficacy safety Actiponin supplementation body weight regulation human lack .</brief_summary>
	<brief_title>Efficacy Safety Actiponin Antiobesity Obese Korean Subjects .</brief_title>
	<detailed_description>The primary aim study investigate effect Actiponin Korean subject body weight fat loss along change metabolic marker base 12 week , randomize , double-blind , placebo-controlled clinical trial . Eighty obesity subject BMI &gt; 25kg/m2 waist-hip ratio ( WHR ) ≥ 0.90 men ≥ 0.85 woman randomly divide either Actiponin ( n=40 , 450mg/day ) placebo group ( n=40 , 450mg/day ) 12weeks .</detailed_description>
	<criteria>BMI ≥ 25kg/m2 WHR ≥ 0.90 ( men ) , WHR ≥ 0.85 ( woman ) Significant variation weight ( 10 % ) past 3 month Cardiovascular disease , e.g . arrhythmia , heart failure , myocardial infarction , patient pacemaker History disease could interfere test product impede theire absorption , gastrointestinal disease gastrointestinal surgery Participation clinical trial within past 2 month Abdominal hepatic liver function Renal disease , e.g . acute/chronic renal failure , nephritic syndrome Used antipsychosis drug therapy within past 2 month Laboratory test , medical psychological condition deem investigator interfere successful participation study Pregnancy breast feed History alcohol substance abuse Allergic hypersensitive ingredient test product</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Actiponin</keyword>
	<keyword>Obesity</keyword>
	<keyword>Abdominal fat</keyword>
</DOC>